IGF-1 LR3 · Research brief

Is Tesamorelin FDA Approved? (Status & Clinical Use Guide)

Real Peptides Research TeamEditorial

Updated April 9, 20269 min read

59 WORDS

Short answer

Tesamorelin 's FDA approval status isn't what most people assume. It holds full FDA approval. But exclusively for HIV-associated lipodystrophy, the condition where antiretroviral therapy causes abnormal visceral fat accumulation. That narrow approval changes everything about how the peptide can be legally prescribed, marketed, and used in research contexts. Our team works with researchers navigating peptide regulatory frameworks daily.

Key takeaways

Tesamorelin received FDA approval in November 2010 exclusively for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. It is not approved for general fat loss, anti-aging, or GH deficiency unrelated to HIV.
The approved dosage is 2mg daily via subcutaneous injection, based on Phase III trials showing 15.2–18.4% mean visceral adipose tissue reduction after 26 weeks.
Compounded tesamorelin contains the same 44-amino-acid peptide as branded Egrifta but is not FDA-approved as a finished drug product. It is prepared by 503B facilities under state pharmacy oversight.
Off-label prescribing of tesamorelin for non-HIV indications is legal but carries different liability and reimbursement implications than on-label use.
Research-grade tesamorelin sold for laboratory use is not FDA-approved and cannot be legally prescribed for human clinical treatment. It exists in a separate regulatory category for preclinical investigation.
Tesamorelin stimulates endogenous growth hormone production rather than supplying exogenous GH, preserving physiological feedback loops and reducing some risks associated with direct GH administration.

Tesamorelin's FDA approval status isn't what most people assume. It holds full FDA approval. But exclusively for HIV-associated lipodystrophy, the condition where antiretroviral therapy causes abnormal visceral fat accumulation. That narrow approval changes everything about how the peptide can be legally prescribed, marketed, and used in research contexts.

Our team works with researchers navigating peptide regulatory frameworks daily. The confusion around tesamorelin FDA approved status stems from a gap between what the compound does physiologically and what the FDA permits it to be sold for.

What is tesamorelin's FDA approved status?

Tesamorelin received FDA approval in November 2010 under the brand name Egrifta, manufactured by Theratechnologies. The approval is strictly limited to reducing excess abdominal fat in HIV-positive patients with lipodystrophy. It is not FDA-approved for general visceral fat reduction, anti-aging therapy, growth hormone deficiency unrelated to HIV, or body composition enhancement in healthy adults. Despite demonstrated effects in those areas.

The distinction matters because off-label prescribing, while legal, carries different liability and reimbursement implications than on-label use. Tesamorelin's mechanism. Stimulating endogenous growth hormone release via GHRH receptor agonism. Works identically whether the patient has HIV or not, but the regulatory pathway recognises only the lipodystrophy indication.

This article covers tesamorelin's exact FDA classification, what the approval permits and prohibits, how compounded versions differ from branded Egrifta, and the regulatory context for research-grade peptide sourcing beyond clinical prescription.

Tesamorelin's FDA Classification and Approved Indication

Tesamorelin is classified as a prescription-only synthetic growth hormone-releasing hormone (GHRH) analogue. The FDA approval granted in 2010 followed two Phase III trials. The LIPODYSTROPHY-I and LIPODYSTROPHY-II studies published in The Lancet. Demonstrating statistically significant reductions in visceral adipose tissue (VAT) measured by CT imaging.

The approval specifies treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. The clinical endpoint was VAT reduction, not weight loss or metabolic improvement, though both occurred as secondary outcomes. Mean VAT reduction in the trials ranged from 15.2% to 18.4% after 26 weeks at the approved 2mg daily subcutaneous dose.

Egrifta (the branded form) remains the only FDA-approved tesamorelin product. Generic versions do not exist because patent protection extends beyond 2026. Compounded tesamorelin. Prepared by 503B outsourcing facilities or state-licensed pharmacies. Contains the same 44-amino-acid peptide sequence but is not FDA-approved as a finished drug product. Compounded preparations are legal under specific conditions, primarily when prescribed for an FDA-approved indication or as part of legitimate research protocols.

The FDA has not approved tesamorelin for visceral fat reduction in non-HIV populations, growth hormone deficiency treatment, sarcopenia, cognitive decline, or any anti-aging application. Those uses constitute off-label prescribing, which is legal but unsupported by FDA review of safety and efficacy data in those populations.

How Tesamorelin Works: Mechanism Beyond the Approval

Tesamorelin binds to GHRH receptors on anterior pituitary somatotrophs, triggering pulsatile growth hormone (GH) secretion that mirrors endogenous circadian patterns. This differs from exogenous GH administration, which suppresses natural production and creates sustained supraphysiological levels rather than physiological pulses.

GH release stimulates hepatic IGF-1 (insulin-like growth factor 1) synthesis, which mediates most of tesamorelin's downstream effects: increased lipolysis in adipocytes, enhanced amino acid uptake in muscle tissue, and improved glucose metabolism. The lipodystrophy trials showed VAT reduction occurred without significant changes in subcutaneous fat. Indicating preferential mobilisation of visceral adipose stores.

The half-life of tesamorelin is approximately 26–38 minutes after subcutaneous injection, but GH elevation persists for 2–3 hours post-dose. Daily dosing maintains therapeutic GH pulsatility without the receptor desensitisation seen with continuous GHRH infusion.

Critically, tesamorelin does not directly supply growth hormone. It prompts the body to produce its own. This preservation of negative feedback loops reduces (but does not eliminate) risks associated with exogenous GH therapy, including insulin resistance and acromegaly-like side effects at supraphysiological doses.

Our experience reviewing peptide research protocols shows this mechanism explains why tesamorelin attracts interest beyond its approved use. The physiological pathway it activates operates identically in HIV-negative populations, even though FDA approval does not extend to those groups.

Tesamorelin FDA Approved Status vs Off-Label Research Use

The tesamorelin FDA approved status creates a regulatory boundary that researchers and clinicians navigate differently depending on context. On-label use. Prescribing Egrifta for HIV-associated lipodystrophy. Falls within the FDA's reviewed and approved framework. Insurance reimbursement, product liability, and medical standard-of-care considerations align with the approval.

Off-label prescribing occurs when a physician prescribes tesamorelin (branded or compounded) for any condition outside the HIV lipodystrophy indication. This is legal under the practice of medicine, provided the prescriber has a legitimate medical rationale and the patient provides informed consent. Common off-label contexts include visceral obesity in metabolic syndrome, age-related GH decline, and body composition optimisation in sarcopenia.

Research-grade tesamorelin exists in a separate regulatory category. Peptides sold explicitly for research purposes. Not human consumption. Are not subject to FDA drug approval requirements. Real Peptides supplies research-grade peptides synthesised under cGMP standards for laboratory and preclinical investigation, distinct from prescription medications dispensed for patient treatment.

The legal distinction hinges on intended use. A physician cannot prescribe research-grade peptides for clinical treatment. That requires a prescription product (Egrifta or compounded tesamorelin from a licensed pharmacy). Conversely, research institutions studying tesamorelin's effects in non-approved populations do not require FDA approval for the study compound itself, though IRB approval and adherence to research ethics standards apply.

This regulatory framework explains why tesamorelin's physiological effects are well-documented in populations beyond HIV patients, even though the FDA approved status remains narrowly defined.

Tesamorelin FDA Approved Status: Branded vs Compounded Comparison

Feature	Egrifta (Branded)	Compounded Tesamorelin	Research-Grade Tesamorelin	Professional Assessment
FDA Approval	Yes. Approved drug product for HIV lipodystrophy	No. Prepared under USP standards but not FDA-approved as finished product	No. Not intended for human consumption	Egrifta is the only FDA-reviewed option; compounded versions use identical peptide but lack batch-level FDA oversight
Prescription Required	Yes. DEA unscheduled but Rx-only	Yes. Must be prescribed by licensed physician	No. Sold for research use only	All clinical use requires prescription; research-grade cannot be legally prescribed
Cost (Typical)	$4,000–$6,000/month retail (often insurance-covered for approved use)	$300–$800/month (not typically covered by insurance)	Variable. Bulk pricing for institutional research	Compounded versions are 80–90% less expensive but require out-of-pocket payment
Quality Assurance	FDA-mandated batch testing, cGMP manufacturing	USP <797> sterile compounding standards, 503B facility oversight	cGMP synthesis with COA (certificate of analysis) provided	Branded product has highest regulatory oversight; 503B compounding is second; research-grade depends on supplier verification
Legal Use Context	On-label prescription for HIV lipodystrophy	Off-label prescription for any legitimate medical purpose	Laboratory research and preclinical studies only	Prescribers assume liability for off-label use; research-grade use in humans violates federal law

What If: Tesamorelin FDA Approved Status Scenarios

What If I Want Tesamorelin for Visceral Fat But Don't Have HIV?

Seek a physician willing to prescribe off-label, understanding insurance will not cover the cost. Compounded tesamorelin from a licensed 503B pharmacy is the practical pathway. Expect $300–$800/month depending on dose and supplier. The prescriber must document a legitimate medical rationale (e.g., metabolic syndrome with elevated VAT confirmed by imaging) and obtain informed consent acknowledging off-label use.

What If My Doctor Prescribes Research-Grade Peptides Instead of Egrifta or Compounded Tesamorelin?

That constitutes illegal prescribing. Research-grade peptides are explicitly labelled 'not for human consumption' and cannot be dispensed as prescription medications. A physician prescribing non-pharmaceutical-grade compounds for patient treatment violates FDA regulations and state medical practice standards. Request a prescription for compounded tesamorelin from a licensed pharmacy instead.

What If I'm Researching Tesamorelin's Effects in Non-HIV Populations?

You can legally source research-grade tesamorelin for preclinical or in vitro studies without FDA approval of the compound itself, provided the research adheres to IRB protocols and federal research ethics standards. Institutional researchers studying tesamorelin's metabolic effects in non-approved populations have published extensively in peer-reviewed journals using non-prescription peptides synthesised to research specifications.

What If Compounded Tesamorelin Costs Less — Is It the Same Quality?

Compounded tesamorelin uses the same amino acid sequence as Egrifta, synthesised to USP standards by FDA-registered 503B facilities. The difference is regulatory oversight: Egrifta undergoes batch-level FDA potency and sterility verification, while compounded versions rely on pharmacy-level quality control. 503B facilities must adhere to cGMP manufacturing and report adverse events, but individual batches are not FDA-tested before dispensing. Reputable compounding pharmacies provide certificates of analysis (COA) showing third-party verification of purity and potency.

The Regulatory Truth About Tesamorelin FDA Approved Status

Here's the honest answer: tesamorelin's FDA approval is real but extremely narrow. It is not a general-purpose fat-loss or anti-aging peptide in the eyes of federal regulators. It is a prescription medication for one specific condition. The physiological effects that make it attractive for broader use (VAT reduction, GH stimulation, metabolic improvement) occur regardless of HIV status, but the regulatory pathway has not expanded to recognise those applications.

This creates a legal and practical gap. Physicians can prescribe it off-label, compounding pharmacies can prepare it under state oversight, and researchers can study it in non-approved populations. But none of those activities change the tesamorelin FDA approved status itself. The approval remains limited to HIV-associated lipodystrophy, and that limitation governs insurance coverage, marketing claims, and product liability frameworks.

For patients seeking tesamorelin outside the approved indication, the path forward is off-label prescribing of compounded preparations. For researchers investigating its effects in metabolic disease, sarcopenia, or cognitive decline, the path is preclinical or clinical trials using research-grade peptides under IRB approval. Both are legal. Neither changes the FDA's position on what tesamorelin is approved to treat.

The regulatory status of peptides like tesamorelin isn't arbitrary bureaucracy. It reflects the FDA's requirement that safety and efficacy be demonstrated in the specific population for which a drug is marketed. Tesamorelin met that standard for HIV lipodystrophy in 2010. It has not yet met it for other indications, despite mechanistic plausibility and emerging evidence.

Understanding the distinction between FDA approval, off-label use, and research applications is essential for anyone considering tesamorelin. Whether as a prescribing clinician, a patient exploring treatment options, or a researcher designing peptide-based interventions. The compound works through well-characterised pathways. The regulatory framework governing its use is equally well-defined. Navigating that framework correctly determines whether tesamorelin can be legally accessed and how it can be responsibly applied.

For laboratories conducting peptide research, sourcing matters. Real Peptides provides research-grade compounds synthesised under cGMP standards with full COA documentation. The baseline expectation for reproducible experimental work. Whether investigating tesamorelin's metabolic effects or exploring related peptides like CJC1295 Ipamorelin or Hexarelin, precision in sourcing translates directly to precision in results.

References

Peer-reviewed sources on Tesamorelin indexed in PubMed, listed for research context. Real Peptides supplies Tesamorelin for laboratory research use only.

Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obesity research & clinical practice, 2026. PMID 41545261. doi:10.1016/j.orcp.2026.01.002
Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs, 2011. PMID 21668043. doi:10.2165/11202240-000000000-00000
Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity. The Journal of infectious diseases, 2025. PMID 39813152. doi:10.1093/infdis/jiaf012
Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS (London, England), 2024. PMID 38905488. doi:10.1097/QAD.0000000000003965
Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial. Journal of clinical and translational science, 2023. PMID 36845310. doi:10.1017/cts.2022.515
Tesamorelin improves fat quality independent of changes in fat quantity. AIDS (London, England), 2021. PMID 33756511. doi:10.1097/QAD.0000000000002897
Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. Scientific reports, 2021. PMID 34006921. doi:10.1038/s41598-021-89966-y
Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI insight, 2020. PMID 32701508. doi:10.1172/jci.insight.140134

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add vials.

Start a pack

Questions

No. Tesamorelin FDA approved status is limited exclusively to reducing excess abdominal fat in HIV-infected patients with lipodystrophy. It is not approved for general weight loss, visceral fat reduction in non-HIV populations, or body composition enhancement in healthy adults. Physicians can prescribe it off-label for those purposes, but such use is not supported by FDA review and insurance will not cover the cost.

Egrifta is the FDA-approved branded tesamorelin product manufactured by Theratechnologies under full FDA oversight, including batch-level potency and sterility testing. Compounded tesamorelin is prepared by 503B outsourcing facilities or state-licensed pharmacies using the same 44-amino-acid peptide sequence but without FDA approval as a finished drug product. Both contain identical active ingredients, but Egrifta costs $4,000–$6,000/month retail while compounded versions cost $300–$800/month and are not typically covered by insurance.

No. Research-grade tesamorelin is sold explicitly for laboratory and preclinical research — not for human consumption. Using it for personal therapy violates federal law, and no physician can legally prescribe research-grade peptides for clinical treatment. If you want tesamorelin for anti-aging or fat loss, you must obtain a prescription for either branded Egrifta or compounded tesamorelin from a licensed pharmacy. Research-grade compounds are intended for institutional research use only.

Tesamorelin stimulates your body’s natural growth hormone production by binding to GHRH receptors in the pituitary gland, triggering physiological GH pulses that mirror endogenous circadian patterns. Direct GH administration suppresses natural production and creates sustained supraphysiological levels rather than pulsatile release. Tesamorelin preserves negative feedback loops, reducing (but not eliminating) risks like insulin resistance and acromegaly-like effects seen with exogenous GH therapy. The half-life of tesamorelin is 26–38 minutes, but GH elevation persists for 2–3 hours post-injection.

The LIPODYSTROPHY-I and LIPODYSTROPHY-II Phase III trials published in The Lancet demonstrated 15.2–18.4% mean visceral adipose tissue (VAT) reduction after 26 weeks at the approved 2mg daily dose in HIV-positive patients with lipodystrophy. The primary endpoint was VAT reduction measured by CT imaging, not total weight loss or metabolic improvement, though both occurred as secondary outcomes. These results led to FDA approval in November 2010 exclusively for the HIV lipodystrophy indication.

No. Insurance companies typically cover tesamorelin only for the FDA-approved indication — HIV-associated lipodystrophy with documented excess visceral fat. Off-label prescriptions for metabolic syndrome, age-related GH decline, or general visceral obesity are almost never reimbursed, making compounded tesamorelin the practical option at $300–$800/month out-of-pocket. Branded Egrifta costs $4,000–$6,000/month retail, which is prohibitive without insurance coverage.

The FDA-approved dosage is 2mg administered once daily via subcutaneous injection, typically in the abdominal area. The medication is supplied as a lyophilised powder that must be reconstituted with sterile water before injection. Dosing occurs at the same time each day to maintain consistent GH pulsatility. The clinical trials used this 2mg daily regimen for 26 weeks, showing peak VAT reduction at that timeframe with sustained effects during continued treatment.

Yes. Tesamorelin is contraindicated in patients with active malignancy (due to GH’s potential role in tumor growth), disruption of the hypothalamic-pituitary axis, or hypersensitivity to the peptide or excipients. Common adverse effects include injection site reactions, arthralgia, and peripheral oedema. Tesamorelin increases IGF-1 levels, which may elevate glucose and HbA1c in some patients — requiring monitoring in those with diabetes or prediabetes. Pregnant or breastfeeding women should not use tesamorelin as safety data in those populations does not exist.

FDA approval requires sponsor-submitted clinical trial data demonstrating safety and efficacy in the specific population for which the drug will be marketed. Theratechnologies has not submitted applications for expanded indications like general visceral obesity or metabolic syndrome, likely due to the cost and complexity of conducting additional Phase III trials. The physiological mechanism operates identically in non-HIV populations, but the regulatory pathway requires formal demonstration of benefit and acceptable risk in each target population before approval can be granted.

Yes. Researchers can legally use research-grade tesamorelin in preclinical studies, in vitro experiments, or clinical trials investigating its effects in non-approved populations, provided the research adheres to IRB protocols and federal ethics standards. Multiple peer-reviewed studies have examined tesamorelin’s metabolic effects in non-HIV cohorts using non-prescription peptides synthesised to research specifications. This research use is distinct from clinical prescribing — research-grade peptides cannot be dispensed as prescription medications for patient treatment.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA